Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Peter Oppelt

Hematology | Oncology
Washington University
150 Entrance Way, St Peters Siteman Cancer C, 
St Peters, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
Washington University
150 Entrance Way, St Peters Siteman Cancer C, 
St Peters, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Peter Oppelt is a Hematologist and an Oncologist in St Peters, Missouri. Dr. Oppelt is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adult Soft Tissue Sarcoma, Laryngeal Cancer, Reconstructive Urology Surgery, and Gastrostomy.

His clinical research consists of co-authoring 156 peer reviewed articles and participating in 41 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Progress West Hospital
Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
150 Entrance Way, St Peters Siteman Cancer C, St Peters, MO 63376
Other Locations
WASHINGTON UNIVERSITY
10 Barnes W Dr, 200 Asthma And Allergy Cente, St Louis, MO 63141
WASHINGTON UNIVERSITY
10 Hospital Dr, Saint Peters, MO 63376
WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110

Additional Areas of Focus

Dr. Oppelt has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

41 Clinical Trials

Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Enrollment Status: Recruiting
Publish Date: May 02, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Cabozantinib, Nivolumab, Ipilimumab
Study Phase: Phase 2
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Vorolanib, Atezolizumab
Study Phase: Phase 2
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drug: Cisplatin
Study Phase: Phase 2
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drugs: Mitomycin C, Pegfilgrastim
Study Phase: Phase 2
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab
Study Phase: Phase 1/Phase 2
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Palbociclib, Cetuximab, Cisplatin
Study Phase: Phase 2
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Olaparib, Pembrolizumab, Carboplatin
Study Phase: Phase 2
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Nab-paclitaxel, Nivolumab
Study Phase: Phase 2
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Ramucirumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Allopurinol, Irinotecan
Study Phase: Phase 1
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug, Procedure
Study Drugs: Cabozantinib, Nivolumab, Abiraterone, Prednisone
Study Phase: Phase 1
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug, Procedure
Study Drugs: CDX-301, CDX-1140
Study Phase: Phase 2
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Enrollment Status: Completed
Publish Date: July 30, 2024
Intervention Type: Drug, Procedure
Study Drugs: Ramucirumab, Atezolizumab
Study Phase: Phase 2
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Genetic, Drug
Study Drugs: Irinotecan, Ramucirumab
Study Phase: Phase 2
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Procedure
Study Drugs: Palbociclib, Letrozole, Fulvestrant, Goserelin
Study Phase: Phase 2
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
Enrollment Status: Terminated
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Pembrolizumab
Study Phase: Phase 1
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drugs: Dexrazoxane, Doxorubicin
Study Phase: Phase 2
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Nivolumab, Ipilimumab, PROSTVAC Shared Antigen Vaccine, Neoantigen DNA Vaccine
Study Phase: Phase 1
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Enrollment Status: Completed
Publish Date: November 24, 2021
Intervention Type: Drug, Radiation, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
Enrollment Status: Withdrawn
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Device, Drug, Other
Study Phase: Phase 1
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Enrollment Status: Terminated
Publish Date: December 03, 2020
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 1/Phase 2
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
Enrollment Status: Withdrawn
Publish Date: August 13, 2020
Intervention Type: Procedure, Device, Drug, Biological
Study Phase: Phase 2
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Enrollment Status: Terminated
Publish Date: July 29, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Enrollment Status: Terminated
Publish Date: July 18, 2019
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 40 Less Clinical Trials

156 Total Publications

Allele frequency selection and no age-related increase in human oocyte mitochondrial mutations.
Allele frequency selection and no age-related increase in human oocyte mitochondrial mutations.
Journal: Science advances
Published: August 06, 2025
Similar Doctors
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Nancy Bartlett
Hematology | Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Nancy Bartlett
Hematology | Oncology

Washington University

10 Barnes W Dr, 200 Asthma And Allergy Cente, 
St Louis, MO 
 (10.2 miles away)
314-996-8670
Languages Spoken:
English
See accepted insurances

Nancy Bartlett is a Hematologist and an Oncologist in St Louis, Missouri. Dr. Bartlett is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Brad S. Kahl
Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Brad S. Kahl
Oncology

Washington University

5201 Mid America Plz, 
Saint Louis, MO 
 (29.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Kahl is an Oncologist in Saint Louis, Missouri. Dr. Kahl is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy. Dr. Kahl is currently accepting new patients.

Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Amanda F. Cashen
Oncology
Elite in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Amanda F. Cashen
Oncology

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (20.2 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amanda Cashen is an Oncologist in Saint Louis, Missouri. Dr. Cashen is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Cashen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oppelt's expertise for a condition
ConditionClose
    View All 26 Distinguished Conditions
    View All 33 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile